Paraneoplastic cerebellar degeneration (PCD) is a rare neuroimmunological disease that may accompany tumors. In this article, we present a patient with progressive gait difficulty who was diagnosed with PCD and, in a rare comorbidity, with papillary thyroid carcinoma (PTC) following malignancy screening. A 46-year-old male patient reported having experienced poor balance for 2 years. A neurological examination revealed nystagmus, intention tremor, and ataxia, and anti-thyroid peroxidase and anti-thyroglobulin levels were found to be elevated. A brain MRI showed significant cerebellar atrophy in the superior vermis. Malignancy screening for PCD was performed, and thyroid ultrasonography revealed a nodule in the left lobe, while PET/CT detected elevated focal F-18 fluorodeoxyglucose uptake in the thyroid. Onconeuronal antibodies (anti-Hu, anti-Yo, anti-Ri, anti-amphiphysin, anti-Tr, anti-PPCA-2, anti-Ma, anti-CV-1, and anti-ANNA-3) were negative. Pathologic examination of the thyroid revealed PTC, for which the patient was treated with 0.4 g/kg intravenous immunoglobulin and referred to the medical oncology department. This case demonstrates that clinicians must be alert to the rare comorbidity of PCD and PTC.
Nonconvulsive status epilepticus (NCSE) is common in patients with coma with a prevalence between 5 and 48%. Nonconvulsive status epilepticus (NCSE) is an electroclinical state associated with an altered mental status (AMS) but lacking convulsive motor activity. It is difficult to diagnose in the obtunded/comatose patients. Such patients have often other serious medical conditions, and the diagnosis of NCSE is frequently delayed in these patients. Diagnosing NCSE demands a high degree of clinical suspicion and for that reason likely remains under-recognized. The most important question, however, is whether the treatment of NCSE in coma improves the outcome of these patients or not. In this review, we aimed to summarize the EEG patterns in NCSE to further delineate the borders between comatose forms of NCSE and coma-epileptiform discharges and to evaluate modified EEG criteria for NCSE in a coma.
OBJECTIVE: This study aimed to evaluate the independent and combined effects of fatigue and walking impairment on multiple sclerosis (MS)-specific quality of life (QoL) and to explore the influence of sociodemographic and clinical factors on these associations.MATERIAL AND METHODS: A multicenter, cross-sectional study was conducted including 181 individuals with MS from four tertiary care centers in Turkey. Patients completed the Fatigue Severity Scale (FSS), the 12-item MS Walking Scale (MSWS-12), and the Multiple Sclerosis Impact Scale (MSIS-29). Sociodemographic and clinical data were collected. Correlation analyses, subgroup comparisons, and multivariate linear regressions were performed to identify predictors of QoL.RESULTS: MSIS-29 scores were strongly associated with MSWS-12 (r=0.81) and moderately associated with FSS (r=0.54) (p<0.001 for both). Multivariate regression demonstrated that walking impairment (β=0.772) and fatigue (β=0.179) were independent predictors of QoL, jointly explaining 70% of the variance in MSIS-29 total scores (R²=0.703). MSWS-12 was the primary predictor of physical QoL, while both MSWS-12 and FSS contributed to psychological QoL. Lower education and comorbidities were associated with worse outcomes in univariate analyses, and female sex was associated with greater disease impact in the multivariable model.CONCLUSIONS: Fatigue and walking limitations are major determinants of reduced QoL in MS, with walking impairment exerting a stronger effect on physical functioning. These results highlight the importance of multidimensional care strategies that address both motor and non-motor symptoms, alongside sociodemographic and clinical characteristics, to optimize individualized MS management.